Targeting drugsensitive and -resistant strains of Mycobacterium tuberculosis by inhibition of Src family kinases lowers disease burden and pathology

Pallavi Chandra, R. S. Rajmani, Garima Verma, Neel Sarovar Bhavesh, Dhiraj Kumar

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

In view of emerging drug resistance among bacterial pathogens, including Mycobacterium tuberculosis, the development of novel therapeutic strategies is increasingly being sought. A recent paradigm in antituberculosis (anti-TB) drug development is to target the host molecules that are crucial for intracellular survival of the pathogen. We previously showed the importance of Src tyrosine kinases in mycobacterial pathogenesis. Here, we report that inhibition of Src significantly reduced survival of H37Rv as well as multidrug-resistant (MDR) and extremely drug-resistant (XDR) strains of M. tuberculosis in THP-1 macrophages. Src inhibition was also effective in controlling M. tuberculosis infection in guinea pigs. In guinea pigs, reduced M. tuberculosis burden due to Src inhibition also led to a marked decline in the disease pathology. In agreement with the theoretical framework of host-directed approaches against the pathogen, Src inhibition was equally effective against an XDR strain in controlling infection in guinea pigs. We propose that Src inhibitors could be developed into effective host-directed anti-TB drugs, which could be indiscriminately used against both drug-sensitive and drug-resistant strains of M. tuberculosis.

Original languageEnglish
Article numbere00043-15
JournalmSphere
Volume1
Issue number2
DOIs
StatePublished - Mar 1 2016

Keywords

  • Adjunct therapy
  • Host-directed therapy
  • MDR-TB
  • XDR-TB

Fingerprint

Dive into the research topics of 'Targeting drugsensitive and -resistant strains of Mycobacterium tuberculosis by inhibition of Src family kinases lowers disease burden and pathology'. Together they form a unique fingerprint.

Cite this